NCT03393611 - CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 30, 2021

Study Completion Date

November 18, 2021

Conditions

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Relapsed Adult Acute MyeloidMyelodysplastic Syndromes, Previously Treated

Interventions

DRUG

CPX-351

Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17

DRUG

Fludarabine

Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)

DRUG

Melphalan

Melphalan 140 mg/m2 (Day -2)

DRUG

Rabbit Anti-Human T-Lymphocyte Globulin

Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)

BIOLOGICAL

Haplo-Cord Stem Cell Transplantation

Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.

Trial Locations (1)

Weill Cornell Medical College, New York